TY - JOUR
T1 - Dihydroartemisinin represses osteoclastogenesis of bone marrow macrophages through reduced NFATc1 expression and impaired phosphorylation of IκBα
AU - Komaki, Shunsuke
AU - Sakai, Eiko
AU - Fukuma, Yutaka
AU - Nishishita, Kazuhisa
AU - Okamoto, Kuniaki
AU - Tsukuba, Takayuki
N1 - Funding Information:
This work was supported by JSPS KAKENHI grant numbers, 15H05298, 16K15790, 16K11480, 16K11863 and 17H04379.
Funding Information:
This work was supported by JSPS KAKENHI grant
Publisher Copyright:
© 2018, Biomedical Research Foundation. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Osteoclasts are multinucleated bone resorbing cells whose differentiation is regulated by several important signaling pathways. Several lines of evidence indicate that dihydroartemisinin (DHA), an anti-malarial drug, inhibits osteoclast differentiation with little cytotoxicity. However, the detailed inhibitory mechanisms of DHA on osteoclastogenesis from native cells remain to be elucidated. In this study, we investigated the effects of DHA on the differentiation of bone marrow-derived macrophages into osteoclasts. DHA inhibited receptor activator of nuclear factor κ-B ligand (RANKL)-induced osteoclast formation and its bone resorbing activity. Mechanistically, DHA treatment markedly abolished phosphorylation of IκBα, and slightly affected a p38 MAPK dependent pathway. Moreover, DHA treatment induced down-regulation of nuclear factor of activated T cells cytoplasmic-1 (NFATc1), a master regulator for osteoclast differentiation and its target proteins, such as Src and cathepsin K. These results indicate that DHA represses RANKL-induced osteoclastogenesis of bone marrow macrophages through reduced NFATc1 expression and impaired phosphorylation of IκBα.
AB - Osteoclasts are multinucleated bone resorbing cells whose differentiation is regulated by several important signaling pathways. Several lines of evidence indicate that dihydroartemisinin (DHA), an anti-malarial drug, inhibits osteoclast differentiation with little cytotoxicity. However, the detailed inhibitory mechanisms of DHA on osteoclastogenesis from native cells remain to be elucidated. In this study, we investigated the effects of DHA on the differentiation of bone marrow-derived macrophages into osteoclasts. DHA inhibited receptor activator of nuclear factor κ-B ligand (RANKL)-induced osteoclast formation and its bone resorbing activity. Mechanistically, DHA treatment markedly abolished phosphorylation of IκBα, and slightly affected a p38 MAPK dependent pathway. Moreover, DHA treatment induced down-regulation of nuclear factor of activated T cells cytoplasmic-1 (NFATc1), a master regulator for osteoclast differentiation and its target proteins, such as Src and cathepsin K. These results indicate that DHA represses RANKL-induced osteoclastogenesis of bone marrow macrophages through reduced NFATc1 expression and impaired phosphorylation of IκBα.
UR - http://www.scopus.com/inward/record.url?scp=85051675938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051675938&partnerID=8YFLogxK
U2 - 10.2220/biomedres.39.169
DO - 10.2220/biomedres.39.169
M3 - Article
C2 - 30101837
AN - SCOPUS:85051675938
VL - 39
SP - 169
EP - 177
JO - Biomedical Research
JF - Biomedical Research
SN - 0388-6107
IS - 4
ER -